{"id":418060,"date":"2025-12-01T21:45:32","date_gmt":"2025-12-01T21:45:32","guid":{"rendered":"https:\/\/www.europesays.com\/us\/418060\/"},"modified":"2025-12-01T21:45:32","modified_gmt":"2025-12-01T21:45:32","slug":"lilly-cuts-price-for-obesity-drug-zepbound","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/418060\/","title":{"rendered":"Lilly cuts price for obesity drug Zepbound"},"content":{"rendered":"

\"play\"<\/p>\n

Trump announces lower prices coming for GLP-1 drugs Zepbound, Wegovy<\/p>\n

President Donald Trump announces discounted pricing for Zepbound and Wegovy and expanding Medicare coverage so more people can access the drugs.<\/p>\n

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug<\/a> Zepbound<\/a> for consumers who buy the prescription medication directly from the drugmaker.<\/p>\n

Lilly’s price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker’s\u00a0LillyDirect<\/a>\u00a0website.<\/p>\n

Customers who buy a month’s supply of 2.5 mg single-dose vials will pay $299, a $50 reduction from the previous price of $349. The 5 mg vials will cost $399, down from $499.<\/p>\n

Four higher dosages \u2013 7.5 mg, 10 mg, 12.5 mg and 15 mg \u2013 will sell for $449. The previous price for higher-dosage vials was $499.<\/p>\n

In a statement, Lilly USA President Ilya Yuffa said far too many people who need obesity medication “still face cost and coverage barriers.”<\/p>\n

The drugmaker’s price cuts “underscores Lilly\u2019s commitment to improving access across the obesity care landscape,” Yuffa said.<\/p>\n

Elsewhere: <\/strong>World Health Organization recommends GLP-1s for obesity. There’s a catch.<\/a><\/p>\n

On Nov. 17, Lilly’s rival Novo Nordisk announced price cuts<\/a> for its weight loss and diabetes drugs Wegovy and Ozempic.<\/p>\n

Novo Nordisk<\/a> dropped the price for injectable Wegovy and Ozempic to $349 a month, down from $499 a month, for consumers who purchase the medication directly from the drugmaker, telehealth partners or retail pharmacies. Only the 2 mg dose of Ozempic will remain at $499 a month.<\/p>\n

Lilly and Novo have been pressured by Trump administration to lower the prices of popular weight loss and diabetes medications. In a deal announced Nov. 6,\u00a0President Donald Trump<\/a>\u00a0said Medicare would cover Novo’s Wegovy and Lilly’s Zepbound for millions of older adults. Trump also said the\u00a0drugmakers would sell discounted versions<\/a>\u00a0of the drugs through the federal government’s direct-to-consumer website, TrumpRx, which will launch in 2026.<\/p>\n

Novo and Lilly agreed to sell the medications to Medicare at an average price of $245 per monthly dose. Medicare enrollees would be charged a monthly copay of $50 to get the weight loss drugs. Medicare expects to launch coverage of the medications in the spring or summer of 2026.<\/p>\n

Lilly said its $50 price for eligible Medicare recipients will extend to a “multi-pen” version of Zepbound and its daily anti-obesity pill orforglipron. Both products must first be approved by the Food and Drug Administration.<\/p>\n

High list prices and limited insurance coverage of glucagon-like peptide-1 drugs, or GLP-1s, have strained affordability for consumers<\/a>. Some consumers face escalating out-of-pocket costs with higher copays or other cost-shifting from their insurance plans.\u00a0<\/p>\n

A survey<\/a> by benefits consultant Mercer found large employers are gradually adding coverage for weight loss medications. In 2025, 49% of large employers covered GLP-1 medications, up from 44% in 2024 and 41% in 2023.<\/p>\n","protected":false},"excerpt":{"rendered":"Trump announces lower prices coming for GLP-1 drugs Zepbound, Wegovy President Donald Trump announces discounted pricing for Zepbound…\n","protected":false},"author":3,"featured_media":418061,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[5672,931,3653,638,2554,446,69,10000,1230,51771,64271,25996,990,3654,2401,210,3168,20738,10667,7337,126182,5948,3235,1060,1186,451,50,10943,12632,450,457,152,101393,153,277,1439,15005,646,67,132,68,6925,428,103,26413],"class_list":{"0":"post-418060","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-administration","9":"tag-and","10":"tag-biotech","11":"tag-company","12":"tag-company-news","13":"tag-donald","14":"tag-donald-trump","15":"tag-drug","16":"tag-drugs","17":"tag-drugs-u0026-medications","18":"tag-eli","19":"tag-eli-lilly","20":"tag-food","21":"tag-glp-1","22":"tag-glp-1-drugs","23":"tag-health","24":"tag-health-insurance","25":"tag-health-news","26":"tag-health-policy","27":"tag-insurance","28":"tag-lilly","29":"tag-loss","30":"tag-medicare","31":"tag-medication","32":"tag-medications","33":"tag-negative","34":"tag-news","35":"tag-obesity","36":"tag-organization","37":"tag-overall","38":"tag-overall-negative","39":"tag-pharmaceuticals","40":"tag-pharmaceuticals-u0026-biotech","41":"tag-policy","42":"tag-trump","43":"tag-u-s","44":"tag-u-s-food-and-drug-administration","45":"tag-u0026","46":"tag-united-states","47":"tag-unitedstates","48":"tag-us","49":"tag-weight","50":"tag-weight-loss","51":"tag-world","52":"tag-world-health-organization"},"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/418060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=418060"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/418060\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/418061"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=418060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=418060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=418060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}